BERLIN, GERMANY AND OREM, UT, UNITED STATES, September 12, 2026 /EINPresswire.com/ — Techcyte, the company behind Fusion—the unified AI platform for anatomic and clinical pathology—announced today that Aignostics has entered the Techcyte Fusion® Partner Program. Together, the two organizations have incorporated Aignostics’ PathoSearch application into Techcyte Fusion AP. This enables pathologists to look for morphologically matching cases directly from within the slide viewer, using the image itself instead of a textual description.
PathoSearch relies on embeddings generated by Atlas 2, Aignostics’ pathology foundation model created in partnership with Mayo Clinic. It compares a chosen region of an H&E whole slide image against a curated, multi-center reference database of diagnosed cases—cases that have been annotated and validated by pathologists. At launch, the database includes more than 310,000 whole slide images drawn from over 35,000 cases, covering over 300 diagnostic entities across 27 organs. For pathologists, this provides a direct means to explore similar cases when they encounter an unusual or unfamiliar finding. For researchers, it offers a method to identify cases with comparable morphology within the reference set.
Inside the Fusion AP slide viewer, users select a region of interest on a given image. Fusion AP then captures and sends that region to PathoSearch, with no export or upload step required. Results are displayed in Aignostics’ platform, showing similar cases along with their associated information. Currently, PathoSearch supports cancers of the thorax, digestive system, soft tissue and bone, female genital tract, and urinary and male genital tract, with additional cancer types planned for future release.
“When a pathologist sees something that doesn’t fit, the useful question is ‘what else looks like this?’ PathoSearch lets them ask it with the image,” said Dr. Tiffany Chen, CMO of Techcyte. “Bringing this into Fusion AP means the reference material is there at the moment it’s needed, letting the pathologist focus on the judgment.”
“This integration is an exciting step in our collaboration, because it seamlessly connects the diagnostic workflow with the image based search engine,” said Dr. Rosemarie Krupar, VP of Pathology at Aignostics. “PathoSearch is built on real, diagnosed cases, annotated and validated by pathologists and aligned to the WHO Classification of Tumours. Fusion AP brings that reference material to pathologists right in the viewer they already work in.”
PathoSearch is currently in early access. Fusion AP users can request access through their Techcyte contact.
Techcyte and Aignostics will be showcasing the integration at the 38th European Congress of Pathology, held September 12–16 in Stockholm. Attendees at ECP are invited to experience the live integrated workflow at booth 539 in Hall B and to discover how PathoSearch works with Fusion AP.
This initial integration marks the first step in the partnership between the two companies. Techcyte and Aignostics intend to introduce additional integrations and capabilities within Fusion AP over the coming months.
PathoSearch and Techcyte Fusion AP are for Research Use Only in the United States and are not intended for diagnostic purposes.
For more details on the Techcyte Fusion Partner Program, visit techcyte.com/partner-program
###
About Techcyte
Techcyte is transforming the practice of pathology through a unified, AI-powered digital platform that streamlines complex workflows, integrates with core lab systems, and enhances communication across the lab.
By partnering with leading laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers, we deliver a unified digital pathology platform to labs and clinics around the world, furthering our mission to positively impact the health of humans, animals, and the environment.
Visit techcyte.com for more information.
Techcyte’s anatomic and clinical pathology platform is for Research Use Only in the United States.
About Aignostics
Aignostics is an artificial intelligence company that delivers AI-powered tissue analyses, validated by pathologists. By combining proprietary access to multimodal clinical data, industry-leading technologies, and rigorous science, Aignostics develops best-in-class products and services for the next generation of precision medicine, supporting both biopharma R&D and clinical routine diagnostics. Established in 2020, Aignostics is a spin-off from Charité Berlin, one of the world’s largest and most esteemed university hospitals. Aignostics is funded by leading investors such as Mayo Clinic and has operations in Berlin and New York.
More information at: www.aignostics.com
Follow us on LinkedIn: www.linkedin.com/company/aignostics
Troy Bankhead
Techcyte
+1 435-210-6200
email us here
